• Natera reported its EXPAND clinical trial of the Fetal Focus single-gene noninvasive prenatal test has enrolled more than 2,000 patients, accelerating recruitment over the past 12 months.
• Initial EXPAND results were already presented in February 2026 in an oral plenary session at the Society for Maternal-Fetal Medicine Annual Meeting.
• The readout showed strong clinical performance, supporting the test’s role in fetal risk assessment for serious early-onset inherited conditions when follow-up paternal carrier testing is not available.
• Management framed the growing dataset as a step toward building higher-quality clinical evidence in single-gene NIPT, a key factor for clinician adoption and broader commercial uptake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605200700BIZWIRE_USPR_____20260520_BW113179) on May 20, 2026, and is solely responsible for the information contained therein.